Purpose: Medical students are at increased risk of poor mental health and need to regularly engage in preventive programs to maintain well-being. However, many do not and it remains an open question whether these programs should be mandatory. We implemented a RCT to examine the effectiveness of assigning medical students to a wellness intervention on adherence to engagement in the assigned intervention and on psychological and academic outcomes. Method: Medical students participated in a 12-week randomized controlled intervention involving one-hour wellness sessions of either (1) yoga; (2) mindfulness; or (3) walking, held twice-weekly. Students completed standardized psychological assessments at baseline and following the intervention. Results: Students randomized to the wellness intervention group engaged in more minutes of assigned activities than students randomized to the control. There was a significant difference in the change from pre-to post-intervention on measures of state anxiety and perceived stress, with better outcomes for the intervention group. Conclusions: The assignment of twice-weekly wellness intervention sessions protects medical students from state anxiety and perceived stress with no negative impact on academic performance. Students adhered to the sessions and reported enjoying the sessions once trying them. Actual engagement is more important than wellness activity type.
Patient: Male, 47-year-old Final Diagnosis: COVID pneumonia • hemophagocytic lymphohistiocytosis (HLH) • HIV infection • Kaposi sarcoma Symptoms: Fever • hepatomegaly • renal failure • respiratory distress • skin lesion Clinical Procedure: — Specialty: Infectious Diseases Objective: Rare coexistence of disease or pathology Background: Hemophagocytic lymphohistiocytosis (HLH) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) can trigger profound immune activation and systemic inflammation, leading to severe, often fatal, conditions. Simultaneously, HIV-infected patients, prone to immune dysregulation, face an increased risk of severe complications from SARS-CoV-2. The optimal timeline for initiating antiretroviral therapy (ART) in patients with severe SARS-CoV-2 and HIV co-infection, especially concerning the risk of HLH, remains uncertain. Case Report: We detail the case of a 47-year-old male with previously undiagnosed HIV who, following ART initiation, developed HLH amid SARS-CoV-2 co-infection. The patient also had biopsy-proven Kaposi Sarcoma with immunoreactivity to Human Herpesvirus 8 (HHV-8), detectable peripheral blood Epstein Barr virus (EBV) DNA PCR and Cytomegalovirus (CMV) DNA PCR, and suspected Pneumocystis jirovecii pneumonia. We believe these conditions contributed to the development of HLH. This case represents a unique report of multiple herpesviruses reactivation, acquired HLH during COVID-19 in a patient with previously undiagnosed HIV. Despite receiving ART, steroids, and appropriate antimicrobial therapy, the patient’s condition did not improve. Conclusions: Further research is required to understand immune dysregulation, including HLH, in patients with HIV and SARSCoV-2 co-infection. The effects of ART initiation on treatment-naïve patients with potential concurrent opportunistic infections and/or herpesvirus reactivation warrant deeper examination to formulate clinical guidelines.
e6813th International Congress on Infectious Diseases Abstracts, Poster Presentations were: staphylococci (303), enterococci (67), streptococci (194), E. coli (141), other Enterobacteriaceae (132), H. influenzae (73), M. catarrhalis (56) and Acinetobacter (16). Interpretive criteria were those of the US-FDA as published in the product package insert.Results: Tigecycline MIC 50 and susceptibility rates among species were identical between sampled years and more potent than either tetracycline or minocycline. The MIC 90 range (mg/L)/% susceptible for ENT was 0.25-4/36-100 with lowest potency noted against Proteae. Amp-C (19-46%) and ESBL strains (4-12%) were tigecycline-susceptible (≤2 mg/L). Only 2 (E. faecalis) Gram-positive cocci (GPC; 0.3%) were tigecycline-non-susceptible at 2 mg/L. The MRSA and MR-coagulase-negative staphylococcal rates were 67 and 84%. No vancomycin-resistant enterococci and only one VISA strain was detected. H. influenzae (MIC 90 , 0.5 mg/L; 40% Bˇ-lactamase-negative ampicillin-resistant) and M. catarrhalis (MIC 90 , 0.25 mg/L) were inhibited by tigecycline, as were all Acinetobacters strains at ≤4 mg/L (bimodal MIC distribution). Tigecycline was not active against P. aeruginosa (MIC 90 , 32 mg/L).Conclusions: Using US-FDA breakpoints, tigecyclineresistant rates among Japanese isolates were nil for Enterobacteriaceae and only 0.3% for GPC. Tigecycline appears to be active against current pathogens from Japan including prevalent resistance phenotypes (extended-spectrum -lactamases, MRSA, penicillin-resistant pneumococci).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.